aa

10
at
12
13
14
15
16
17

= ltem6of17 <q Se a) A fcc] Pr
Question ta: 1234 . 4 Mark Previous Next Full Screen 2 Lab a Notes Calculator _ Reverse Color
Zeracizumab is an experimental angiogenesis inhibitor targeting vascular endothelial growth
factor that is being tested for the treatment of advanced, chemotherapy-naive, non-squamous
non-small cell lung cancer (NSCLC). Part of the drug company's evaluation process is to
analyze the 1-year survival after treatment to determine the clinical efficacy of the experimental

treatment. The results are given in the table below.

Zeracizumab-containing
Standard chemotherapy

regimen
Alive at 1 year 40 il
Dead at 1 year 60 69

Which of the following best represents the number needed to harm for the zeracizumab-
containing regimen?

GAA)

Text Zoom

eu.
1) B25
Â©) C.40
Activate Windows
Block Time Elapsed: 00:00:26
Tutor % Feedback

Suspend

63

Settings

()

End Block

